CervoMed finalizes Phase 3 design for Lewy Body Dementia amid tight cash runway
CervoMed (NASDAQ:CRVO) announced on Tuesday that it has achieved critical regulatory and clinical alignment for the Phase 3 development of neflamapimod, its oral small-molecule treatment for dementia with Lewy bodies (DLB).










